Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Saturday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

BTX opened at $0.43 on Friday. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10. The firm has a 50 day moving average price of $0.94 and a 200 day moving average price of $1.51. The company has a market cap of $25.30 million, a PE ratio of -0.19 and a beta of 4.61.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.